---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-024430"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:20:26.134902+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma reports CC-42344 active against avian H5N1 PB2; Phase 2a results expected H2 2024

## Summary
- In vitro studies show CC-42344 inhibits the PB2 protein of avian influenza A (H5N1) strain from infected dairy cattle.
- Phase 2a clinical trial of oral CC-42344 in influenza A subjects ongoing; topline results expected in second half of 2024.
- CC-42344 binds to highly conserved PB2 region; high barrier to resistance and broad-spectrum activity highlighted.
- CDC reports first human H5N1 cases from dairy cows; company notes no FDA-approved vaccine for humans against this strain.
- Positive Phase 1 safety/tolerability data reported in 2022; structure-based platform used to confirm binding.

## SEC filing metadata
- accession: 0001493152-24-024430
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315224024430/0001493152-24-024430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315224024430/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-024430
- JSON: https://secwatch.observer/filing/0001493152-24-024430.json
- Plain text: https://secwatch.observer/filing/0001493152-24-024430.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.